Their results revealed that the single injection efficacy of AAV2-VEGF-Trap significantly inhibited the growth of the glioma, demonstrating antiangiogenic properties comparable to Bev, the standard anti-VEGF therapy. The gene discussed is VEGFA; the disease is glioma.